Liquid biopsy allows non-invasive detection and analysis of tumor-derived biomarkers in body fluids like blood, urine, and saliva, aiding in early detection, therapy selection, and disease monitoring. Liquid biopsy has the potential to expands access to precision medicine in cases where tissue biopsies are unavailable, have low tumor content or fail quality control metrics. Illumina’s broad liquid biopsy portfolio includes Pillar small panels, TruSight Oncology500 ctDNA v2 for comprehensive genomic profiling, and even exome and whole genome sequencing. Find out how Illumina’s library prep uses dual-strand unique molecular indexing (UMIs) and the DRAGEN enrichment pipeline, to minimize the risk of false positive, and lower the limit of detection while maintaining high specificity.

The key things you will learn in this webinar are:

• Liquid Biopsy in Precision Medicine – Non-invasive tumor biomarker detection for early diagnosis, therapy selection, and monitoring.
• Illumina’s Liquid Biopsy Portfolio – Solutions from small panels to whole genome sequencing.
• Enhanced Accuracy & Sensitivity – Dual-strand UMIs and DRAGEN pipeline reduce false positives and improve detection.

Speaker:

Joel Geoghegan Commercial Segment Lead, Oncology, Illumina Joel Geoghegan is responsible for driving Illumina’s oncology strategy for Africa, the Middle East and Asia. He is focused on enabling precision medicine at scale to maximise improvement in outcomes for cancer patients. This includes expanding access to next-generation sequencing technology to aid in the diagnosis, prognosis, therapy selection and monitoring of patients.​  Joel has over 25 years of experience working in the genomics industry. This includes research fellowships at the National Cancer Institute, R & D positions within the biotech industry, and running a genomics facility within a pathology setting. Focus and expertise on new technologies has led to numerous collaborations with key opinion leaders around the world resulting in publications in Nature Genetics, Nature Methods, PNAS, Human Mutation, Blood and Leukaemia.